CERo Therapeutics Holdings, Inc. CERO
$0.01
$0.004.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 605.40K | 605.40K | 605.40K | 500.00K | -- |
| Gross Profit | -605.40K | -605.40K | -605.40K | -500.00K | -- |
| SG&A Expenses | 10.39M | 10.96M | 10.65M | 9.64M | 10.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.09M | 19.67M | 19.93M | 17.50M | 17.04M |
| Operating Income | -18.09M | -19.67M | -19.93M | -17.50M | -17.04M |
| Income Before Tax | -16.31M | -20.70M | -19.92M | -14.71M | -14.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.31 | -20.70 | -19.92 | -14.71 | -14.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.31M | -20.70M | -19.92M | -14.71M | -14.08M |
| EBIT | -18.09M | -19.67M | -19.93M | -17.50M | -17.04M |
| EBITDA | -17.83M | -19.40M | -19.65M | -17.18M | -16.68M |
| EPS Basic | -13.23 | -74.24 | -105.86 | -149.69 | -310.81 |
| Normalized Basic EPS | -2.83 | -9.65 | -28.15 | -50.72 | -154.71 |
| EPS Diluted | -13.23 | -74.24 | -105.86 | -149.69 | -310.81 |
| Normalized Diluted EPS | -2.83 | -9.65 | -28.15 | -50.72 | -154.71 |
| Average Basic Shares Outstanding | 87.18M | 45.49M | 16.91M | 1.98M | 741.40K |
| Average Diluted Shares Outstanding | 87.18M | 45.49M | 16.91M | 1.98M | 741.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |